N-Methyl-PPPA
Source: Wikipedia, the free encyclopedia.
Chemical compound
Clinical data | |
---|---|
Other names | Detrifluoromethylfluoxetine |
ATC code |
|
Identifiers | |
| |
JSmol) | |
| |
|
N-Methyl-PPPA, or N-methyl-3-phenoxy-3-phenylpropan-1-amine, is a
serotonin-norepinephrine reuptake inhibitor (SNRI) which was developed by Eli Lilly from diphenhydramine in the early 1970s while in search of new antidepressants, but was never marketed.[1][2][3] It is closely related structurally to fluoxetine, atomoxetine, and nisoxetine.[1][2][3]
See also
- 3-Phenoxy-3-phenylpropan-1-amine (PPPA)
- Development and discovery of SSRI drugs
- Aryloxypropanamine scaffold
References
- ^ ISBN 978-1-4398-3850-1.
- ^ ISBN 978-0-470-01552-0.
- ^ PMID 7623609.
| ||
---|---|---|
SNRIs Tooltip Serotonin–norepinephrine reuptake inhibitors | ||
NRIs Tooltip Norepinephrine reuptake inhibitors | ||
NDRIs Tooltip Norepinephrine–dopamine reuptake inhibitors | ||
NaSSAs Tooltip Noradrenergic and specific serotonergic antidepressants | ||
SARIs Tooltip Serotonin antagonist and reuptake inhibitors | ||
SMS Tooltip Serotonin modulator and stimulators | ||
Others |
|
TCAs Tooltip Tricyclic antidepressants |
| |
---|---|---|
TeCAs Tooltip Tetracyclic antidepressants | ||
Others |
|
|
Miscellaneous | |
---|---|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
Corporate directors | |
---|---|
Products |
|